Physician profile
Amanda Mata
NPI 1174050272
$1,790.01
in general payments reported to CMS, 2019-2025
26 companies · $826 in 2025
The $826 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $470 · 2023: $72.10 · 2024: $138 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.12 |
| Education | $259.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.10 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $183.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.36 | 2024 | Jardiance |
| Evofem Biosciences, INC. | $88.97 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $80.00 | 2025 | |
| Seagen INC. | $79.99 | 2025 | |
| Ironshore Pharmaceuticals INC. | $72.23 | 2022 | |
| Janssen Biotech, INC. | $70.93 | 2025 | Talvey, Darzalex, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $69.60 | 2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $62.78 | 2025 | Enhertu |
| Hologic Sales and Service, LLC | $56.94 | 2022-2023 | Aptima |
| Exeltis, USA INC. | $56.25 | 2021-2023 | Slynd |
| Glaxosmithkline, LLC. | $53.36 | 2025 | Ojjaara, Blenrep |
| Astellas Pharma US INC | $35.35 | 2025 | Xtandi, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $34.92 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $32.03 | 2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $26.26 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $24.99 | 2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $23.12 | 2025 | Iclusig |
| Genzyme Corporation | $23.01 | 2025 | |
| Merck Sharp & Dohme LLC | $20.09 | 2025 | Keytruda Qlex, Keytruda |
| Organon LLC | $18.55 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.06 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $15.01 | 2025 | Opdivo |
| Agile Therapeutics, INC. | $13.70 | 2022 | |
| Novo Nordisk INC | $13.34 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.